Temasek Holdings (Private) LTD Bei Gene, Ltd. Transaction History
Temasek Holdings (Private) LTD
- $24.5 Billion
- Q3 2024
A detailed history of Temasek Holdings (Private) LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Temasek Holdings (Private) LTD holds 2,388,576 shares of BGNE stock, worth $464 Million. This represents 2.19% of its overall portfolio holdings.
Number of Shares
2,388,576Holding current value
$464 Million% of portfolio
2.19%Shares
17 transactions
Others Institutions Holding BGNE
# of Institutions
249Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.05 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.25 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.01 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$966 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$720 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...